Estrogen receptor-alpha (ERa) is an important biomarker used to classify and direct therapy decisions in breast cancer (BC). Both ERa protein and its transcript, ESR1, are used to predict response to tamoxifen therapy, yet certain tumors have discordant levels of ERa protein and ESR1, which is currently unexplained. Cellular ERa protein levels can be controlled post-translationally by the ubiquitin-proteasome pathway through a mechanism that depends on phosphorylation at residue S118. Phospho-S118 (pS118-ERa) is a substrate for the peptidyl prolyl isomerase, Pin1, which mediates cis-trans isomerization of the pS118-P119 bond to enhance ERa transcriptional function. Here, we demonstrate that Pin1 can increase ERa protein without affecting ESR1 transcript levels by inhibiting proteasome-dependent receptor degradation. Pin1 disrupts ERa ubiquitination by interfering with receptor interactions with the E3 ligase, E6AP, which also is shown to bind pS118-ERa. Quantitative in situ assessments of ERa protein, ESR1, and Pin1 in human tumors from a retrospective cohort show that Pin1 levels correlate with ERa protein but not to ESR1 levels. These data show that ERa protein is post-translationally regulated by Pin1 in a proportion of breast carcinomas. As Pin1 impacts both ERa protein levels and transactivation function, these data implicate Pin1 as a potential surrogate marker for predicting outcome of ERa-positive BC.
INTRODUCTION
Estrogen receptor-alpha (ERa) is a nuclear receptor expressed in breast epithelial cells, functioning as a hormone-regulated transcription factor. ERa determination in breast cancer (BC) patients is critical for disease management, as elevated ERa associates with better outcome and substantial benefit to endocrine therapy. 1, 2 Yet, in BC patients and tumor models, defects in ERa protein regulation are associated with increased risk and metastasis, [3] [4] [5] and targeted ERa overexpression in mammary epithelial cells of transgenic mice results in ductal and lobular hyperplasias. 6 The control of ERa expression is a fundamental regulatory system governing receptor activity in BC tumor biology and important for BC prognosis and treatment, [6] [7] [8] but is not completely understood. Quantitative measurements of ERa mRNA (ESR1) transcripts in human BC using both DNA microarray and in situ methods have shown a positive, but non-linear, relationship between ERa protein and its transcripts. 9, 10 Although tumors with high ESR1 occur frequently with high ERa protein, cases with low ESR1 show variations in ERa protein levels. 9 Structure-function analyses have defined domains of ERa that control receptor protein levels. ERa contains two transactivation domains, activation function 1 (AF1) and activation function 2 (AF2), located at the N-terminal domain (NTD) and C-terminal domain (CTD), respectively. 11 We previously reported that S118 phosphorylation (pS118) in AF1 is essential for ERa protein turnover via the ubiquitin-proteasome pathway. 12 The S118 site resides in a serine/threonine-proline (S/T-P) motif, where the proline can adopt a cis or trans conformation. [13] [14] [15] [16] Pin1, a prolyl cis/trans isomerase, binds to pS/T-P motifs through its WW domain and catalyzes cis/trans isomerization of substrates by its PPIase domain. 13, [15] [16] [17] [18] Pin1 binds to pS118 and causes cis-trans isomerization of the phospho-S118-P119 (pS118-P119) bond of ERa, which translates into increased ERa transcriptional function. We previously showed that Pin1 increases ERa activity via activation of AF1 and increases growth of BC cells in the presence of tamoxifen. 19 Similar to ERa, Pin1 is overexpressed in a proportion of BC, and its expression is associated with increased cell proliferation in rodent tumor models. [19] [20] [21] [22] We report, herein, that Pin1 stabilizes ERa protein by blocking receptor interaction with the E3 ligase, E6AP, at S118 and inhibiting E6AP-mediated ubiquitination. Though Pin1 isomerase function is important in increasing ERa transcriptional function, 19 Pin1 binding was sufficient to prevent receptor ubiquitination and degradation. Quantitative in situ measurements in human tumor samples show that Pin1 and ERa levels are positively associated, wherein high Pin1 correlates with elevated ERa, but not ESR1 mRNA transcripts, reinforcing the biological importance of posttranslational regulation of ERa and Pin1 in human BC patients.
RESULTS

Pin1 inhibits ERa protein degradation
Serine 118 in the N-terminus of ERa is an important cis-element governing receptor protein turnover, and is likewise the interaction site of Pin1 with ERa. 12, 19 These findings prompted the question whether Pin1 affected ERa protein levels in cells. We employed multiple approaches to answer this question.
Immunocytochemistry data showed that knockdown of Pin1 does not alter ERa localization but prominently decreased the staining intensity of both ERa and pS118-ERa proteins (Figure 1a ). This effect of Pin1 on ERa protein was not due to changes in gene expression as knockdown of Pin1 did not change ESR1 mRNA relative to controls (Figure 1b) . Western blot analyses showed that decreasing Pin1 levels in ERa-positive BC cells, MCF-7 ( Figure 1c ) and T47D (Figure 1e ), by small interfering RNA (siRNA), reduced ERa protein in both the presence and absence of 17-beta estradiol, E2. The E2-induced loss of ERa protein significantly increased from 58 to 79% in Pin1 siRNA transfected MCF-7 cells compared with controls (Figure 1d ), and this loss was prevented by pre-treatment with proteasome inhibitor, MG132 (Figures 1c  and d) . To confirm the effect of loss of Pin1 on ERa protein, mouse embryonic fibroblast (MEF) cells from Pin1 knock-out (Pin1 À / À ) and wild-type (WT) mice were transfected with HA-ERa and treated with E2 for various lengths of time. Similar to transient knockdown studies, ERa turnover was accelerated in Pin1 À / À compared with WT cells (Supplementary Figure 1a) . Next, we conducted rescue experiments to determine if Pin1 regulates ERa stability through a mechanism that depends on interactions between ERa and Pin1. Re-expression of Pin1 in MEF Pin1
À / À cells rescued expression of a transfected HA-tagged ERa protein, confirming that Pin1 stabilizes ERa protein. ERa mutants that do not bind Pin1, S118A and S118E, 19 were not affected by Pin1 expression in the presence of estrogen (Figures 2a and b) . However, both the S118 A and E mutations were intrinsically stable relative to WT receptor, confirming the importance of S118 Figure 1 . Loss of Pin1 accelerates proteasome-mediated degradation of ERa. (a) Immunofluorescence microscopy of MCF-7 cells transfected with Pin1 siRNA or control scrambled (scr) siRNA and treated with E2 for 2 h. Fixed cells were incubated with an anti-ERa or anti-pS118ERa antibody and stained with DAPI for nuclear staining. (b) MCF-7 cells were transfected with Pin1 siRNA or control scr siRNA. The cells were treated with EtOH or E2 for 2 h, and qRT-PCR was used to analyze the expression of ERa mRNA, ESR1. Data shown are relative to those of the EtOH-treated control (left-most bar), and data are represented as means ± s.e.m. for three independent experiments. (c, d) MCF-7 cells were transfected with Pin1 siRNA or control scr siRNA, and 72 h after transfection, cells were pretreated with and without 10 mM MG132, a proteasome inhibitor, for 30 min followed by EtOH ( À ) or 10 nM E2-treatment for 2 h. Levels of ERa, Pin1 and actin (loading control) were assessed by western blot analysis and (d) bands were quantified by densitometry and represented as a graph normalized to EtOH-treated samples. Data are represented as means ± s.e.m. for three independent experiments. Asterisks indicate a statistically significant difference between scr siRNA and Pin1 siRNA E2-treated cells (*Po0.05), using Student's t-test, and % denotes changes between EtOH and E2-treated samples. (e) T47D cells were transfected as in (c) and treated with EtOH ( À ) or 10 nM E2 ( þ ) for 2 h. Levels of ERa, Pin1 and actin were assessed by western blot analysis.
to the regulation of ERa protein. 12 Thus, to further test the effect of Pin1-ERa interactions on receptor stability, we examined the function of Pin1 mutants on WT ERa. We previously showed that a single-point mutation in the WW domain, W34A, disrupts Pin1 interaction with ERa. 19 WT Pin1 increases ERa protein expression, as expected, but the Pin1-binding mutant, W34A, was unable to stabilize ERa (Figure 2c) To confirm these findings in BC cells, E2-induced ERa proteolysis was assessed in MCF-7 cells stably overexpressing GFP-Pin1 or GFP as a control. Similar to MEF cells, Pin1 attenuated the loss of ERa compared with control MCF-7 GFP cells (Figure 2d ) and the relative amount of ubiquitinated ERa following E2-treatment was diminished in Pin1-overexpressing cells (Figure 2e) . Altogether, these results show that Pin1 binding to receptor modulates ERa protein stability by inhibiting ubiquitin-proteasome-mediated degradation.
The E3 ligase, E6AP, binds ERa in a S118-dependent manner ERa ubiquitination can be mediated by multiple ligases, [24] [25] [26] [27] [28] [29] depending on the signal inducing degradation. E6AP is a HECT-domain ligase that targets the receptor for ubiquitination and degradation, and its loss attenuates E2-induced ERa downregulation 26, 30 and (Supplementary Figure 1b and c). Our previous chromatin immunoprecipitation data showed that S118 phosphorylation can control E6AP recruitment to ERa transcriptional complexes. 12 Co-immunoprecipitation (Co-IP) studies were thus carried out in MCF-7 cells to validate endogenous E6AP interactions with ERa. In agreement with previous reports, 26, 30 E6AP and ERa interact in both MCF-7 ( Figure 3a ) and T47D (Supplementary Figure 1d) BC cells. Surprisingly, E6AP was found in complex with ERa in both the presence and absence of E2.
To map the sites of ERa that mediate E6AP interactions, mutant ERa lacking the CTD (ERa DCTD) or NTD (ERa DNTD) (Figure 3b , upper panel) were expressed in ERa-negative 293T cells, and Co-IP experiments were performed using ERa antibodies followed by western blot for E6AP. E6AP bound to both ERa deletion mutants. Previous studies had shown that E6AP binds to the ERa CTD through the receptor coactivator interaction domain. 31 The interaction with the ERa DCTD, however, implies that E6AP can interact with ERa through both N-and C-terminal domains. Co-IP experiments using antibodies targeting pS118 also showed that E6AP was in complex with pS118ERa ( Figure 3c ). To directly examine if E6AP and ERa interaction requires phosphorylated S118, Co-IP experiments were performed in cells stably overexpressing HA-ERa, HA-ERa S118A or HA-ERa S118E. A strong (d) MCF-7 cells stably expressing GFP or GFP-Pin1 were treated with and without 10 nM E2 for the indicated length of time, and western blot was performed for ERa, GFP and actin. (e) MCF-7 cells overexpressing GFP or GFP-Pin1 were treated with 10 mM MG132 for 30 min followed by 4 h treatment with 10 nM E2 ( þ ) or EtOH ( À ). ERa was immunoprecipitated using anti-ERa antibody and the level of ubiquitination was evaluated by western blot using anti-ubiquitin antibody (Ub).
interaction between E6AP and WT ERa was observed, and this interaction was lost in S118 mutants (Figures 3d and e) . Similar results were observed in MCF-7 cells with tet-inducible expression of HA-ERa and S118 mutants (Supplementary Figure 1e) . Reciprocal experiments wherein E6AP immunoprecipitates were probed for ERa showed that WT ERa formed a stronger complex with E6AP than the S118A mutant (Figure 3f ), though binding to an S118A mutant was observed. Taken together, these data suggest that E6AP binds to both the N-and C-terminal domains of ERa, and an intact S118 site is important in stabilizing these interactions.
Pin inhibits E6AP-mediated ERa ubiquitination in vitro
Data shown above indicate that Pin1 interferes with ERa ubiquitination, and that Pin1 and E6AP bind the same site on ERa, suggesting possible competition between Pin1 and E6AP. To test this possibility, an in vitro approach was taken using purified components. GST-E6AP and Pin1 were purified, and the level of purity was examined by coomassie stained SDS-PAGE (Supplementary Figure 2a and b) . GST-E6AP, but not GST, was precipitated with purified recombinant ERa, which was phosphorylated at S118 (Figure 4a ). We previously showed, using Far Western experiments, that Pin1 binds directly to pS118ERa. 19 These data together indicate that both E6AP and Pin1 can bind directly to ERa protein. An in vitro ERa ubiquitination assay was then conducted, using ubiquitin activating enzyme E1 (Ube1), ubiquitin conjugating enzyme E2 (UbcH5a), ATP, ubiquitin and purified ERa, in the absence and presence of increasing amounts of GST-E6AP. Western blots for ERa showed an increase in higher migrating ERa protein species, indicating that ERa was ubiquitinated by E6AP in a dose-dependent manner (Figure 4b ). Addition of increasing amounts of Pin1 resulted in a gradual disappearance of higher migrating ERa protein species (Figure 4c ). Addition of juglone, a catalytic inhibitor of Pin1, 32 was without effect. Hence, the catalytic activity of Pin1 was dispensable for blocking E6AP-mediated ubiquitination of ERa (Figure 4d ). These data show that E6AP can bind and ubiquitinate ERa and that Pin1 can directly interfere with E6AP-mediated ERa ubiquitination in a dose-dependent manner. Figure 3 . The E3 ligase, E6AP, binds ERa in a S118-dependent manner. (a) MCF-7 cells were pretreated with or without 10 mM MG132 for 30 min and then treated with and without 10 nM E2 and 10 mM MG132 for 4 h. Cells were harvested and ERa was immunoprecipitated by ERa antibody or normal rabbit IgG, and western blot was performed for E6AP and ERa. Input lanes represent E6AP and ERa in cell extracts before immunoprecipitation. (b) Schematic representation of regions corresponding to full-length ERa, ERa DCTD and ERa DNTD. Also shown is the location of AF1, AF2 and S118P sites (upper panel). 293T cells were transfected with plasmid HE15 expressing ERa DCTD or HE19-expressing ERa DNTD. Twenty-four hours post-transfection, cells were treated as in (a) and ERa DCTD was immunoprecipitated with N-terminus specific ERa antibody (H184, Santa Cruz Biotechnology) and ERa DNTD with C-terminus specific ERa antibody (HC-20, Santa Cruz Biotechnology), or rabbit IgG, and western blot was performed with respective ERa antibodies and E6AP. (c) MCF-7 cells were treated as in (a) and immunoprecipitated with pS118-ERa antibody or mouse IgG, and western blot was performed for E6AP. (d, e) 293 cells stably expressing HA-ERa, HA-ERa S118A (d) or HA-ERa S118E (e) were treated as in (a) and ERa was immunoprecipitated with HA antibody and western blot was performed for E6AP and HA. (f ) 293 cells stably expressing HA-ERa or HA-ERa S118A were treated as in (d) and E6AP was immunoprecipitated with E6AP antibody or rabbit IgG, and western blot was performed for HA.
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Pin1 blocks E3 ubiquitin-ligase E6AP and ERa interaction
The present data suggest a model wherein ERa protein can be either stabilized or degraded depending on whether Pin1 or E6AP binds to phosphorylated ERa. Figure 3c) , confirming that E6AP is an ERa-targeting ligase. We next asked if overexpression of Pin1 could rescue E6AP-mediated ERa degradation. Cells were co-transfected with ERa and E6AP in the presence and absence of Pin1. Consistently, E6AP expression resulted in ERa protein downregulation (Figure 5b ). However, expression of Pin1 could partially revert the ERa protein loss at high levels of E6AP. This rescue was specific to Pin1 as FKBP51, another prolyl isomerase, was unable to prevent E6AP-mediated ERa turnover (Figure 5b) .
It is possible that Pin1 could indirectly control substrate stability by enhancing the turnover of the E3 ligase. [33] [34] [35] Examining E6AP levels following Pin1 overexpression showed no apparent difference in E6AP levels (Supplementary Figure 3d) . However, Co-IP analysis showed that overexpression of Pin1 in MCF-7 cells decreased E6AP interactions with ERa compared with cells expressing FKBP51 (Figure 5c ). Moreover, overexpression of a Pin1-binding mutant (W34A) failed to disrupt E6AP interactions (Figure 5d ). These results indicate that ERa is degraded by E6AP and that Pin1 can spare ERa protein by blocking ERa:E6AP binding.
Pin1 and ERa protein expression show positive correlation in human breast carcinoma Pin1 is overexpressed in BC and is crucial for the growth of ERa-positive BC cells and tumors in rodent models. [19] [20] [21] [22] As Pin1 directly modulates both ERa protein turnover and transcriptional function, we next explored the relationship between ERa and Pin1 in human breast tumors using quantitative immunofluorescence in tissue microarrays (TMAs) of human BC samples. As depicted in Figure 6a , Pin1 protein was allocated predominantly in the tumor compartment and showed a pan-cellular staining pattern (nuclear and perinuclear signal). Distribution of Pin1 scores on a Yale Pathology retrospective cohort (Supplementary Table 1) showed a wide range, and Pin1 protein expression was homogeneous (Supplementary Figure 4) . As expected, ERa was detected only in the nuclear compartment. Interestingly, ERa levels were positively (non-linearly) associated with Pin1 levels on the Yale Pathology TMA201 (YTMA-201) (R 2 ¼ 0.24, Po0.001; Figures 6a and b) . This concordance between Pin1 and ERa protein levels on serial tumor sections is evident on Figure 6a , showing representative cases of Pin1 high/ERa high and Pin1 low/ERa low tumors.
As previously reported, 9 ESR1 transcripts were detected almost exclusively in the tumor compartment, as relatively small punctate signals located throughout the cells (Figure 6e ). As opposed to ERa, ESR1 transcript levels were not positively related with Pin1 (R 2 ¼ 0.04). Moreover, tumors with high Pin1 scores showed Btwo-fold higher (Po0.001) ERa levels than those with low Pin1 tumors (Figure 6c ). In the same population, in situ ESR1 levels were comparable to the Pin1 low and elevated group (Figure 6d) .
Finally, as a proof of concept, survival analysis of cases from the YTMA-201 showed that ERa-positive BC cases with Pin1 AQUA scores above the median cohort value (Pin1 high cases, score46729) display lower overall survival than cases with low Pin1 levels (Pin1 AQUA score o6729, log-rank P ¼ 0.0182) (Figure 6f ).
DISCUSSION
These studies provide evidence that identifies Pin1 as a new regulatory component controlling ERa protein expression levels in The demonstration that Pin1 prevents ERa protein degradation extends the functional role of Pin1 in ERa biology and provides a plausible explanation for the paradoxical role of phosphorylation in receptor proteolysis and transcriptional function. ERa proteolysis requires cis-elements in the N-terminal transactivation domain in addition to the C-terminal hormone-dependent transactivation domain. 12, 36, 37 Although this is outwardly consistent with the generalized model, wherein degradation and transcriptional activity are coupled, 30, [38] [39] [40] exceptions to this model exist suggesting that the two pathways can be independently regulated. 12, 19, 41, 42 In the case of ERa, activation of both proteolytic and transcription activation pathways involves phosphorylation at S118; 12, 36, 37 however, several observations suggest a complex regulation of phosphorylated ERa. There are conflicting data which indicate that phosphorylation can both accelerate and inhibit receptor proteolysis. 12, [43] [44] [45] [46] Moreover, S118 mutations that stabilize ERa protein have opposite effects on receptor transcriptional function. 12 Our data provide a possible explanation for this paradox by demonstrating that when phosphorylated at S118, ERa becomes a substrate for Pin1, which can differentially regulate receptor protein stability as well as function. Mass spectrometry of ERa in MCF-7 cells indicates that as much as 48% of total ERa is phosphorylated at S118. 47 Pin1 binding to pS118 prevents ERa interactions with the E3 ligase, E6AP and stabilizes receptor protein. However, under conditions where Pin1 is absent or low, E6AP can bind phosphorylated ERa, ubiquitinate and target the receptor for degradation. Conditions of high Pin1, such as can be found in certain human tumors as shown in Figure 6 , favor a stable ERa protein. Hence, phosphorylated ERa can be protected or targeted for degradation depending on the relative levels of Pin1.
Subsequent to binding, Pin1 can isomerize the S-P motif and increase transcriptional activity of the N-terminal AF1. 19 Unlike the effect on receptor protein stability, the activity of Pin1 on receptor transcriptional function requires Pin1 isomerase activity. The isomerization of ERa augments the total transcriptional activity of ERa and enhances ligand-independent receptor transcription. 19 The Pin1-induced increase in receptor AF1 transcriptional function is also sufficient to increase the activity of the tamoxifen-bound receptor 19 and support growth of BC cells in the presence of tamoxifen. 19, [48] [49] [50] These data suggest the possibility that Pin1 can differentially regulate the stability and transcriptional activity of phosphorylated ERa by utilizing independent functions of binding and isomerization. Together, our results point to Pin1 as a downstream regulator of phosphorylated ER, which modulates both receptor fate and function and, thereby, can alter the functional consequences associated with the phosphorylated receptor.
This model may apply to other nuclear receptors and transcription factors in which phosphorylation at S/T-P motifs controls stability and transactivation. Phosphorylation affects the stability of several nuclear receptors, including PR, RARa, PPARa, GR, AR, ERb and ERa. [51] [52] [53] Pin1 binding in the absence of isomerization was sufficient to block polyubiquitination of PPARg. 35 Pin1 increases both transcriptional function and protein stability of NF-kB, c-jun, b-catenin, PPARg, TR3, p53 and p73 proteins. 21, 35, [54] [55] [56] [57] [58] [59] Similarly to ERa, Pin1 binding to p65 inhibits p65 interaction with IkBa and an E3 ligase, SOCS-1, resulting in increased NFkB activity and nuclear accumulation. 58 It is important to note that Pin1 does not stabilize all substrates nor does all regulation by phosphorylation of transcription factors involve S/T-P motifs. However, our data suggest the possibility, that given the high proportion of transcriptional activation domains with S/T-P motifs regulated by phosphorylation, that Pin1 may have a broader role as a decision point guiding the coordination of transcriptional activity and protein stabilization.
Though several ligases are implicated in the regulation of ERa, [24] [25] [26] [27] [28] [29] this study focused on E6AP because of its well-described role in BC and data linking E6AP with phosphorylation at S118.
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E6AP protein expression is decreased in human invasive BC, and overexpression of ubiquitin-ligase defective E6AP initiates mammary tumor development, implicating an important role of E6AP ligase activity in tumor suppression. 60, 61 E6AP also interacts with other nuclear receptors, partially because it contains three signature LXXLL motifs (nuclear receptor interacting motifs) that bind to the CTD of nuclear receptors. 31 The binding of E6AP with receptor CTD is associated with its transcriptional coactivator function, which can be functionally uncoupled to its ligase activity. 31 Chromatin immunoprecipitation analysis provided the first evidence that E6AP recruitment to ERa transcriptional complexes was dependent on the NTD. 12 Analyses of estrogen receptor-b (ERb) also showed that E6AP binds at phosphorylated residues, pS94/106, in the AF1 region of the NTD to mediate its polyubiquitination. 62 We now show that pS118 in ERa is also an interaction site for E6AP. Given the association of pS118 with ERa degradation, it is plausible that interactions mediated through the receptor NTD impart specificity for ligase-dependent functions of E6AP in ER regulation. Sun et al. 30 recently reported another E6AP interaction site in ERa at Y537, which controls liganddependent ERa proteolysis. 30 In contrast to their report, we find that E6AP binding to ERa is ligand-independent in agreement with Reid et al., 39 however, this interaction required proteasome inhibition to detect. The ligand-independent interaction of E6AP and S118 could be explained by growth factor-induced phosphorylation of ERa by factors in charcoal-stripped serum. 63 In either case, the data suggest that E6AP may have a role in both ligand-dependent and ligand-independent activities that could also be impacted by Pin1.
The biological relevance of the Pin1-mediated increase in ERa protein is confirmed by our findings in human BC samples ( Figure 6 ). The absence of BC cases without any Pin1 signal and the positive association between ERa and Pin1 protein levels in BC samples suggest that not only Pin1 presence but also increased levels account for elevated ERa protein levels. The latter is consistent with the in vitro observation of Pin1 inhibition of E6AP binding to ERa leading to reduced receptor degradation. Moreover, the absence of increased ESR1 transcripts in BC with elevated Pin1 and ERa levels further supports this notion and might explain why a proportion of BC with elevated ERa levels do not show proportionally increased ESR1 transcripts. These findings could have clinical implications, as ESR1 was recently shown to be a strong linear predictor of tamoxifen response in BC and low ESR1 levels were suggested to be a determinant of tamoxifen resistance, independent from ERa levels. 64 In addition to the effects on ERa protein levels, Pin1 augments the ligand-independent activity of ERa and supports increased transcriptional function and growth in the presence of tamoxifen in BC cells. 19 Therefore, Pin1-overexpressing tumors might represent a unique group of ERa-positive BC with high ERa protein, low ESR1 levels and reduced tamoxifen sensitivity. Pin1 overexpression may, therefore, have utility as a surrogate marker for prediction of tamoxifen resistance. In support of this notion, preliminary survival analysis of cases from the YTMA-201 show that ERa-positive BC cases with high Pin1 levels display lower overall survival (Figure 6f ). Further studies are required to confirm and extend these observations in human tumors.
MATERIALS AND METHODS
Plasmids, purified proteins, and reagents
Generation of plasmids encoding Flag-Pin1, Flag-Pin1 K63A, Flag-Pin1 W34A, Flag-FKBP51, HA-ERa, HA-ERa S118A, HA-ERa S118E, ERa in the LHL-CA backbone were all described previously. 19 Plasmids expressing ERa DCTD (HE15) and DNTD (HE19) were provided by Dr Pierre Chambon. 65 Flag-bTrCP1 was a gift from Dr Vladimir Spiegelman (UW-Madison). Plasmids expressing HA-E6AP and Glutathione S-transferase (GST) tagged E6AP were gifts from Dr Robert Kalejta (UW-Madison) and GST-Pin1 was described previously. 19 GST-E6AP and GST-Pin1 were purified using glutathione affinity purification as previously described. 19 For Pin1 purification, GST was cleaved using thrombin (Invitrogen, Carlsbad, CA, USA), using the manufacturer's protocol.
Cell culture and treatments
MCF-7, MEF Pin1 knockout (MEF Pin1
À / À ) and wild-type (MEF WT, MEF Pin1 þ / þ ) cells, 66, 67 MCF-7 cells stably expressing GFP or GFP-Pin1, 19 tet-inducible MCF-7 derivative and 293 cells stably expressing HA-ERa, HAERa S118A and S118E, 7,12 T47D, 293T, and MDA-MB-231 cells were maintained as described. 19 In experiments involving treatment with hormone 17b-estradiol (E2) or vehicle ethanol (EtOH-), cells were placed in estrogen-deprived medium consisting of phenol-red free DMEM (Cellgro, Manassas, VA, USA) with 10% dextran charcoal-stripped fetal bovine serum supplemented with L-glutamine and penicillin/streptomycin, for 3 days before the addition of hormone or vehicle.
Western blot analyses
Western blot was performed as described. 12 ERa antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA or Vector Laboratories, Burlingame, CA, USA) was used to detect endogenous ERa, Flag antibody (Sigma, St Louis, MO, USA) to detect Flag-bTrCP1, Flag-FKBP51 or Flag-Pin1 and mutants, hemagglutinin (HA) antibody (Santa Cruz Biotechnology) to detect HA-E6AP, HA-ERa and mutants, GFP antibody (Cell Signaling, Danvers, MA, USA) for GFP or GFP-Pin1, GST antibody (Santa Cruz Biotechnology) for GST or GST-E6AP, ubiquitin antibody (Santa Cruz Biotechnology) to detect ubiquitnated ERa, and actin antibody (Sigma) as a loading control.
Immunofluorescence microscopy
Pin1 siRNA or control scrambled (scr) siRNA (Qiagen, Valencia, CA, USA) were transfected in MCF-7 cells using Lipofectamine (Invitrogen). Seventytwo hours post-transfection, cells were treated with E2 for 2 h and immunofluorescence microscopy was performed as described. 7 Primary antibodies included ERa (HC-20; Santa Cruz Biotechnology), pERa-S118 (Cell Signaling), Pin1, 68 and DAPI (4 0 ,6-diamidino-2-phenylindole dihydrochloride; Sigma). Secondary antibodies included either anti-mouse IgG-fluorescein isothiocyanate (Sigma) or anti-rabbit IgG-rhodamine red (Molecular Probes, Grand Island, NY, USA). Images were acquired using an Olympus fluorescence microscope with Â 20 magnification and exported to Adobe Photoshop for image analysis (Olympus, center valley, PA, USA).
Ubiquitination assay
Stable MCF-7 cells expressing GFP or GFP-Pin1 were placed in medium containing dextran charcoal-stripped serum for 3 days. Cell were pretreated with 10 mM MG132 (Calbiochem, Billerica, MA, USA) for 30 min to allow accumulation of ubiquitinated intermediates. Cells were then treated with EtOH or 10 nM E2 for 4 h. ERa ubiquitination was assessed by immunoprecipitation (IP) for ERa (H184; Santa Cruz Biotechnology), followed by western blot for ubiquitin (Santa Cruz Biotechnology).
Co-immunoprecipitation
Estrogen-deprived cells were pretreated with and without 10 mM MG132 (Calbiochem) for 30 min and then treated with EtOH or 10 nM E2 and with or without 10 mM MG132 for 4 h. Cells were harvested, and IP was performed as described 69 with antibodies pS118-ERa (Cell Signaling), ERa (H184), HA, E6AP antibodies, or IgG (all purchased from Santa Cruz Biotechnology) and western blot was performed for E6AP, ERa, HA or GFP (Cell Signaling). For experiments involving Pin1 overexpression, MCF-7 cells were transfected with 4 mg of Flag-Pin1, -W34A or -FKBP51 for 24 h and IP was performed as described above, followed by western blot for E6AP, ERa and Flag using appropriate antibodies. For experiments, involving ERaDCTD and ERaDNTD binding to E6AP, 293T cells were transfected with 5 mg of HE15 (DCTD) or HE19 (DNTD) plasmids for 24 h, and IP was performed with NTD antibody (H184), CTD or IgG (all purchased from Santa Cruz Biotechnology). Western blot was then performed for E6AP and ERa using antibodies directed towards ERa NTD or CTD.
In vitro IP
IPs were performed with purified recombinant ERa (Invitrogen) and GST-E6AP or GST. Complex formation was allowed to proceed at 4 1C for 2 h, followed by overnight incubation with ERa antibody or IgG (Santa Cruz Biotechnology) at 4 1C. The next day, protein-A-sepharose beads were added to the antibody-protein complex and incubated for 1 h at 4 1C and washed with IP buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 10% glycerol, 2 mM EDTA and 50 mM NaF). Beads were boiled, and western blot was performed for GST (Santa Cruz Biotechnology), pS118 (Cell Signaling) or ERa (H184; Santa Cruz Biotechnology).
In vitro ubiquitination assay
Assays were performed with 0-1 mg of GST-E6AP, 50 ng Ube1 (Boston Biochem, Cambridge, MA, USA), 100 ng UbcH5a (Boston Biochem), 10 mg ubiquitin (Boston Biochem), 2 mM adenosine triphosphate (ATP; Invitrogen), and 40 ng of purified recombinant ERa (Invitrogen) in the presence and absence of Pin1 (0-1 mg) and 7.5 mM juglone (Sigma) in a 30-ml reaction volume for 1.5 h at 30 1C. The reaction was stopped using sodium dodecyl sulfate (SDS) sample buffer and the reaction mixture was analyzed by western blot using ERa antibody (H184; Santa Cruz Biotechnology)
RNA isolation and quantification MCF-7 cells were transfected with Pin1 or scr siRNA and 48 h posttransfection cells were treated with EtOH or 10 nM E2 for 2 h and then harvested. RNA isolation and quantitative real-time PCR (qRT-PCR) for ERa gene, ESR1, were carried out as previously detailed. 69 Ribosomal protein P0 mRNA was used as the internal control. Relative RNA levels were calculated using the DDCt method. 
Tissue immunofluorescence (IF) staining
Stainings were performed using a standard indirect IF protocol as recently described. 9, 71 Briefly, TMAs serial sections were simultaneously stained with cytokeratin, DAPI and Pin1 (1:1000) 68 or ERa (clone SP1 1:1000, Thermo Scientific, Dr Hanover Park, IL, USA). All stained slides were kept at room temperature and light protected for o12 h before image acquisition and processing.
RNA in situ hybridization
In situ mRNA measurement for ESR1 transcripts was performed using the RNAscope formalin-fixed parrafin-embedded assay kit (Advanced Cell Diagnostics, San Francisco, CA, USA) according to the manufacturer's instructions, with modifications for fluorescence detection using Cy5-tyramide as recently described. 9 Quantitative fluorescence analysis Analysis was performed using the AQUA method allowing continuous and objective measurement of fluorescence intensity within defined tissue areas, as well as within subcellular compartments, as described. 9, 71 Briefly, a series of monochromatic high-resolution images were captured using an Olympus AX-51 epifluorescent microscope using a previously described algorithm for image collection. 72 A tumor mask was created by creating a binary cytokeratin signal. Target probe expression was quantified only in the tumor area. AQUA scores were calculated for a given target within the tumor mask by dividing the signal intensity by the area of the tumor mask within the histospot. Patient sample histospots containing o3% tumor, determined by the percentage area positive for cytokeratin, were excluded from the analysis.
